THALOMID CAPSULE

País: Canadá

Idioma: inglés

Fuente: Health Canada

Ingredientes activos:

THALIDOMIDE

Disponible desde:

CELGENE INC

Código ATC:

L04AX02

Designación común internacional (DCI):

THALIDOMIDE

Dosis:

200MG

formulario farmacéutico:

CAPSULE

Composición:

THALIDOMIDE 200MG

Vía de administración:

ORAL

Unidades en paquete:

28

tipo de receta:

Prescription

Área terapéutica:

Immunomodulatory Agents

Resumen del producto:

Active ingredient group (AIG) number: 0152770004; AHFS:

Estado de Autorización:

APPROVED

Fecha de autorización:

2010-08-04

Ficha técnica

_ _
_ _
_Page 1 of 53_
PRODUCT MONOGRAPH
Pr
THALOMID
®
Thalidomide Capsules
House Standard
50 mg, 100 mg, 200 mg
Immunomodulatory Agent
SUBMISSION CONTROL NO: 283297
®
THALOMID is a registered trademark of Celgene Corporation used under
license by Bristol-Myers Squibb
Canada.
Bristol-Myers Squibb Canada
2344 Alfred-Nobel Blvd
Suite 300
Saint-Laurent, QC
H4S 0A4
DATE OF INITIAL AUTHORIZATION:
MAR 01, 2024
_ _
_ _
_Page 2 of 53_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION................................................................3
SUMMARY PRODUCT INFORMATION
....................................................................................3
INDICATIONS AND CLINICAL USE
..........................................................................................3
CONTRAINDICATIONS
...............................................................................................................5
WARNINGS AND PRECAUTIONS
..............................................................................................5
ADVERSE REACTIONS
..............................................................................................................15
DRUG INTERACTIONS
..............................................................................................................23
DOSAGE AND ADMINISTRATION
..........................................................................................25
OVERDOSAGE
............................................................................................................................29
ACTION AND CLINICAL PHARMACOLOGY
........................................................................30
STORAGE AND STABILITY
......................................................................................................33
SPECIAL HANDLING INSTRUCTIONS
...................................................................................33
DOSAGE FORMS, COMPOSITION AND PACKAGING
.........................................................33
PART II: SCIENTIFIC INFORMATION
...